



PRESS RELEASE, November 8, 2019

Linnane Pharma acquires large block of shares in SelectImmune Pharma AB

Linnane Pharma, the Parent Company of SelectImmune Pharma AB, has acquired the block of shares in the company that was previously held by Bengt Furberg, the Board member who recently passed away. The shares were acquired from the estate of Bengt Furberg and the price was based on the recent average share price. The purchase has strengthened Linnane's holding in SelectImmune by 200,000 shares.

The employees at Lund University who are leading the research that forms the basis of SelectImmune's activities acquired shares in the company in conjunction with the listing. All of the researchers, including Catharina Svanborg, have signed a shareholder agreement to strengthen the joint commitment to the company.

For more information, please contact:

Catharina Svanborg

Chairman of the Board, SelectImmune Pharma AB, and owner of Linnane Pharma AB

Telephone +46 709 42 65 49

E-mail: Catharina.Svanborg@med.lu.se

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.